UK dividends payout in Q1 totals £18.8bn. Will it last?

Monday, Apr 30 2012 by
2

I doubt it . . .

U.K. dividend payouts soared by 25% in the first quarter of 2012 to reach £18.8bn, according to the latest Dividend Monitor report from Capita Registrars, which analyses data provided by Exchange Data International. In total, British firms paid out £3.8bn more than the same period in 2011, making 2012 a record for the first quarter.

The headline total dividend payout for Q1 was boosted by two very large distorting factors. Vodafone and Cairn Energy each paid out £2.2bn in the form of special dividends. Vodafone's reflects the strong performance at Verizon Wireless, in which it owns a 45% shareholding, while Cairn was returning cash to shareholders on the disposal of assets in India.

But will it last?

Capita expects an acceleration in U.K. dividend payouts as the year progresses, providing the eurozone doesn't implode again. Capita has cut its underlying forecast growth rate to 8.2% for the full year to reflect the slower first quarter.

Click For more  


Filed Under: Income Investing,

Disclaimer:  

Steven Dotsch - Managing editor - http://www.dividend-income-investor.com - Guide to Dividend Investing, at: http://www.dividend-income-investor.com/guide-to-dividend-investing/ - Dividend Value Profiles, at:   http://www.dividend-income-investor.com/british-american-tobacco/


Do you like this Post?
Yes
No
2 thumbs up
0 thumbs down
Share this post with friends



Vodafone Group Plc (Vodafone) is a telecommunications company. The Company's business is organized into two geographic regions: Europe, and Africa, Middle East and Asia Pacific (AMAP). Its segments include Europe and AMAP. Its Europe segment includes geographic regions, such as Germany, Italy, the United Kingdom, Spain and Other Europe. The Other Europe includes the Netherlands, Portugal, Greece, Hungary and Romania, among others. Its AMAP segment includes India, South Africa, Tanzania, Mozambique, Lesotho, Africa, Turkey, Australia, Egypt, Ghana, Kenya, New Zealand and Qatar, among others. The Company provides a range of services, including voice, messaging and data across mobile and fixed networks. The Company acquires spectrum and licenses to use radio frequencies that deliver mobile services. Its fixed capabilities include cable, fiber and copper networks to enable television, broadband and voice services. more »

LSE Price
223.7p
Change
-0.2%
Mkt Cap (£m)
59,558
P/E (fwd)
27.9
Yield (fwd)
5.8
81

Cairn Energy PLC (Cairn) is a United Kingdom-based independent oil and gas exploration and development company. The Company's portfolio is focused on approximately three geographical regions, such as North West Europe, the Atlantic Margin and the Mediterranean. Cairn has exploration and appraisal assets in the Atlantic Margin, North West Europe and the Mediterranean, and core development assets in the North Sea. The Company has interests in over two the United Kingdom North Sea developments, Catcher and Kraken, and a third development, Skarfjell. Cairn holds approximately 40% interest in over three contiguous blocks offshore Senegal. The Company's subsidiaries include Capricorn Oil Limited, Cairn UK Holdings Limited, Capricorn Spain Limited, Capricorn Malta Limited, Capricorn Greenland Exploration A/S, Capricorn Exploration and Development Company Limited, Capricorn Mauritania Limited, Capricorn Senegal Limited and Capricorn Ireland Limited. more »

LSE Price
169.9p
Change
-0.1%
Mkt Cap (£m)
990.9
P/E (fwd)
n/a
Yield (fwd)
n/a

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects. more »

LSE Price
5401p
Change
-1.9%
Mkt Cap (£m)
68,363
P/E (fwd)
18.2
Yield (fwd)
4.0



  Is Vodafone fundamentally strong or weak? Find out More »


What's your view on this thread? Log In to Comment Now

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis